NCT03253172Active, not recruiting
Potassium Supplementation in CKD
Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease (CKD)
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The current high-sodium, low-potassium diet contributes to the high prevalence of high blood pressure (hypertension). Indeed, the anti-hypertensive effects of potassium supplementation are well-established. Hypertension is even more prevalent and resistant in patients with chronic kidney disease (CKD) and contributes to further decline in kidney function. Four recent epidemiological studies (published 2014 - 2016) showed that higher dietary potassium intake was associated with better renal outcomes. All studies recommended an intervention study with potassium supplementation in patients with CKD, but this has not been performed. The aim of this study is to study the renoprotective effect of potassium supplementation in patients with CKD (stage 3b or 4, i.e. estimated glomerular filtration rate \[eGFR\] 15 - 45 ml/min/1.73 m2).
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 532 (estimated)
- First submitted
- 15 Aug 2017
- Start date
- 1 Jul 2017
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Erasmus Medical Center
- NCT number
- NCT03253172
What you commit to
- Study type: Interventional
- Planned participants: 532
- From 1 Jul 2017 to the primary completion date, 1 Sept 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous history of ventricular cardiac arrhythmia
Lab values
- Hyperkalemia (serum potassium \> 5.5 mmol/l) at study visit V0
- Medical reasons to continue dual RAAS-blockade, mineralocorticoid receptor blockers, potassium-sparing diuretics, or oral potassium binders.
Age
- Expected initiation of renal replacement therapy \< 2 years
Other
- Patients with a life expectancy \< 6 months
- Incapacitated subjects
- Women who are pregnant, breastfeeding or consider pregnancy in the coming 2 years.
Who the study is looking for
- CKD 3b or 4 (45 - 15 ml/min/1.73 m2)
- Δ eGFR (as estimated by the CKD-EPI equation) \> 2 ml/min/1.73 m2/year (in preceding ≥ 1 year with at least 3 measurements)
- Hypertension (defined as office blood pressure \> 140/90 mmHg or use of anti-hypertensive medication)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Academic Medical Center Amsterdam Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
| Leiden University Medical Center Coordinator of this site? Confirm its status | Leiden | Netherlands | Unknown status |
| Erasmus MC Coordinator of this site? Confirm its status | Rotterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.